SEC 13F Intelligence

Palo Alto Investors LP / RVNCEUR

Palo Alto Investors LP’s Revance Therapeutics Inc Position

Does Palo Alto Investors LP own Revance Therapeutics Inc (RVNCEUR)? Not currently — the last reported position was 1.61M shares worth $8M in Q3 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$8M
Q3 2024
Shares
1.61M
% of Portfolio
+1.09%
Quarters Held
20
position exited

Position History RVNCEUR

Reported value by quarter
Q4 ’19: $1MQ4 ’19Q1 ’20: $9MQ2 ’20: $42MQ3 ’20: $50MQ3 ’20Q4 ’20: $76MQ1 ’21: $89MQ2 ’21: $95MQ2 ’21Q3 ’21: $89MQ4 ’21: $71MQ1 ’22: $86MQ1 ’22Q2 ’22: $61MQ3 ’22: $119MQ4 ’22: $98MQ4 ’22Q1 ’23: $170MQ2 ’23: $132MQ3 ’23: $60MQ3 ’23Q4 ’23: $46MQ1 ’24: $26MQ2 ’24: $14MQ2 ’24Q3 ’24: $8Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 20241.61M$8M+1.09%
Q2 20245.26M$14M+1.57%
Q1 20245.25M$26M+2.91%
Q4 20235.24M$46M+4.15%
Q3 20235.23M$60M+5.67%
Q2 20235.23M$132M+10.69%
Q1 20235.27M$170M+14.06%
Q4 20225.28M$98M+8.32%
Q3 20224.41M$119M+9.40%
Q2 20224.41M$61M+5.31%
Q1 20224.42M$86M+6.66%
Q4 20214.37M$71M+4.56%
Q3 20213.20M$89M+5.38%
Q2 20213.20M$95M+5.23%
Q1 20213.20M$89M+5.10%
Q4 20202.67M$76M+3.97%
Q3 20201.99M$50M+2.75%
Q2 20201.70M$42M+2.50%
Q1 2020615.7K$9M+0.76%
Q4 201988.6K$1M+0.08%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Palo Alto Investors LP’s full portfolio or all institutional holders of RVNCEUR.